Dapoflit MV Tablet is a clinically effective triple-drug oral formulation combining Dapagliflozin 10mg, Metformin 1000mg, and Vildagliptin 100mg, designed for comprehensive glycemic management in patients with type-2 diabetes mellitus who require intensified therapy.
Dapagliflozin facilitates glucose excretion via the kidneys, Metformin reduces hepatic glucose production and improves insulin sensitivity, while Vildagliptin enhances incretin-mediated insulin secretion. Together, these mechanisms provide optimal control of fasting and postprandial blood glucose levels.
This combination is ideal for patients inadequately controlled on dual therapy, offering improved glycemic stability with a favorable safety profile. It is commonly prescribed by diabetologists and physicians for long-term management of chronic diabetes.
Adding Dapoflit MV Tablet to your diabetes and metabolic-care portfolio strengthens your market offerings, creating opportunities in retail pharmacy supply, hospital procurement, institutional distribution, export markets, and third-party manufacturing. Its high prescription demand ensures consistent commercial performance.